<DOC>
	<DOC>NCT03090542</DOC>
	<brief_summary>In healthy subjects not receiving or requiring lipid lowering therapy and who do not have diabetes, the use of clinoptilolite (GPUR) will result in a reduction of absorbed dietary cholesterol observed over 6 days of therapy.</brief_summary>
	<brief_title>GPur- Luminating Oral Cholesterol Kinetics Pilot Study</brief_title>
	<detailed_description />
	<criteria>Adults over 18 years of age Not receiving or requiring lipid lowering therapy Willingness to give informed consent Able to keep a dietary log Willing to maintain a consistent day to day routine during the study (no major changes in lifestyle, exercise, food pattern, smoking habits, etc) Current use of oral lipid binding agents (colesevelam, cholestyramine, ezetimibe) fibrates, niacin or statins Current use of dietary supplements enriched with fat soluble vitamins, mono/polyunsaturated fat (fishoil etc.) or probiotics Any oral antibiotic use, currently or within the past 14 days Diabetes, Type I and Type II Currently following a restrictive diet GI motility disorders (irritable bowel syndrome, diabetic gastroparesis, etc) Prior gastric or bowel resection Inflammatory bowel disease (Crohns, ulcerative colitis, diverticulitis, celiac sprue, etc) Comorbidities with anticipated life expectancy &lt; 12 months ESRD on dialysis Known intolerance to silicium or aluminum compounds Excess alcohol consumption (&gt;1 drink per day) Pregnancy, nursing or not taking/using contraception Hepatobiliary disorders or renal disease Plasma total cholesterol &gt; 240mg/dl or Triglycerides &gt; 265.5 mg/dl No plantsterol enriched food products allowed in diet &amp; supplements BMI &gt; 35</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>